L Wu1, T Evans. 1. Instituto de Cirugía Ocular, San José, Costa Rica. LW65@cornell.edu
Abstract
PURPOSE: To report the immediate changes of intraocular (IOP) pressure after an intravitreal injection of 2.5mg (0.1 ml) of bevacizumab. METHODS: Prospective, non-controlled, interventional case series of 45 patients undergoing intravitreal injection of 2.5mg (0.1 mL) of bevacizumab for a variety of retinal disorders. IOP was measured with a Goldmann tonometer at baseline, immediately after, 30 minutes and one day after injection in all of the cases. The main outcome measured was the IOP immediately after injection. RESULTS: At baseline the mean IOP was 16.6±2.8mm Hg (range, 10-24 mm Hg; median, 16 mm Hg; 25(th) percentile, 14 mm Hg and 75(th) percentile, 18 mm Hg). IOP rose to 53.9±18.2mm Hg (range, 16-78 mm Hg, median, 54 mm Hg; 25(th) percentile, 40 mm Hg and 75(th) percentile, 70 mm Hg; p<0.001) immediately after the injection. After 30 minutes, the IOP normalized but was still higher than baseline with a mean of 19.8±5.2 mm Hg (range, 10-36 mm Hg; median,18 mm Hg; 25(th) percentile,16 mm Hg and 75(th) percentile, 24 mm Hg; P<.01). At 24 hours the IOP was 15.7±3.1 mm Hg (range,10-24 mm Hg; median, 16 mm Hg; 25(th) percentile,14 mm Hg and 75(th) percentile,18 mm Hg; p>0.05). CONCLUSIONS: An intravitreal injection of 2.5mg (0.1 ml) of bevacizumab causes a transient elevation of IOP that tends to return to normal 30 minutes later.
PURPOSE: To report the immediate changes of intraocular (IOP) pressure after an intravitreal injection of 2.5mg (0.1 ml) of bevacizumab. METHODS: Prospective, non-controlled, interventional case series of 45 patients undergoing intravitreal injection of 2.5mg (0.1 mL) of bevacizumab for a variety of retinal disorders. IOP was measured with a Goldmann tonometer at baseline, immediately after, 30 minutes and one day after injection in all of the cases. The main outcome measured was the IOP immediately after injection. RESULTS: At baseline the mean IOP was 16.6±2.8mm Hg (range, 10-24 mm Hg; median, 16 mm Hg; 25(th) percentile, 14 mm Hg and 75(th) percentile, 18 mm Hg). IOP rose to 53.9±18.2mm Hg (range, 16-78 mm Hg, median, 54 mm Hg; 25(th) percentile, 40 mm Hg and 75(th) percentile, 70 mm Hg; p<0.001) immediately after the injection. After 30 minutes, the IOP normalized but was still higher than baseline with a mean of 19.8±5.2 mm Hg (range, 10-36 mm Hg; median,18 mm Hg; 25(th) percentile,16 mm Hg and 75(th) percentile, 24 mm Hg; P<.01). At 24 hours the IOP was 15.7±3.1 mm Hg (range,10-24 mm Hg; median, 16 mm Hg; 25(th) percentile,14 mm Hg and 75(th) percentile,18 mm Hg; p>0.05). CONCLUSIONS: An intravitreal injection of 2.5mg (0.1 ml) of bevacizumab causes a transient elevation of IOP that tends to return to normal 30 minutes later.
Authors: Matthew D Karl; Jasmine H Francis; Saipriya Iyer; Brian Marr; David H Abramson Journal: J Pediatr Ophthalmol Strabismus Date: 2017-01-17 Impact factor: 1.402